To determine the possible changes in RANK and RANKL expression induced by dual HER2 blockade, gene expression profiling was performed in paired surgical tumor samples obtained before and following treatment with lapatinib and trastuzumab (and endocrine therapy if the tumor was hormone receptor-positive) from the PAMELA phase II clinical trial [22]. This evidence concerns the gene TNFSF11 and neoplasm.